AXIS Clinicals LLC and Joanneum Research Forschungsgesellschaft mbH
Phase 1/1b, 2a,2 and 3 AXIS Partnership Solutions
AXIS is supporting clinical research for NDA, 505(b)(2) Pharmacology Enabling Clinical Projects Ophthalmology, Oncology, Dermatology & Others Encompassing full-service CRO support Phase 1 Early Stage Capabilities: First in Human/Proof-of-concept Pharmacokinetic/Pharmacodynamics Single Ascending Dose (SAD) Multiple Ascending Dose (MAD) Drug-Drug Interaction (DDI) Food Effect (FE) Gender and Age Effect Renal Impaired Studies Hepatic Impaired Studies Cardiac Safety Studies US Patient Trials Therapeutic Areas: Ophthalmology Glaucoma, Cataracts, Contact Lens, Cornea, Refractive Indications,…
AXIS Clinicals US Patient trials Expansion: Oncology, Ophthalmology, Dermatology
AXIS Clinicals US Patient trials Expansion: Ophthalmology, Dermatology, Oncology AXIS Clinicals, a CRO offering clinical pharmacology services addressing needs of the evolving clinical research industry, and our clients, AXIS Clinicals has established as an extension of our organization the following therapeutic experts to advance our services bringing targeted patients into trials earlier within the drug development process. In addition to performing First-in-Human, Single Ascending Dose/Multiple Ascending dose pharmacology projects, AXIS can offer patient overnight confinement at our…
AXIS Clinicals US Patient trials Expansion: Oncology, Ophthalmology, DermatologyRead More
AXIS Clinicals, a Clinical Research Organization, welcomes Dr. Keith Gallicano as a consultant as the Senior Advisor in Clinical & Scientific Affairs. DILWORTH, MN, 1st March, 2021 – AXIS Clinicals added another member as part of the consultation team with the welcoming of Dr. Keith Gallicano as the Senior Advisor in Clinical and Scientific Affairs. Keith Gallicano, Ph.D. (Chemistry) is a consultant in clinical pharmacology and biopharmaceutics with expertise in…
AXIS Continues Clinical Research During COVID-19 Restrictions
Dilworth, MN – Clinical and bioanalytical studies supporting pharmacology projects and multi-site patient trials continue at AXIS. Various projects supporting research to address the Coronavirus pandemic and other critical research for oncology, neurology, women’s health, and other key therapeutic areas are ongoing. We have placed critical polices for safety and sanitization protocols for staff and participants. Daily reviews are being undertaken to ensure that our facilities and overall operations continue…
AXIS Continues Clinical Research During COVID-19 RestrictionsRead More
AXIS Clinicals Announces ERT Certification.
Dilworth, MN – Axis Clinicals USA announces they have received ERT Certification. The Certification program ensures sites are proficient in collecting the highest quality ECG data. This is done by conducting Phase I QT assessments using ERT’s proprietary Expert Precision QT approach. With Axis Clinicals being ERT certified, we are able to work with biopharmaceutical clients making recommendations on the design, conduct, analysis, and interpretation of continuous Holter recordings to…
Axis Clinicals hires Dr. Michael Willett
Dilworth, MN- AXIS Clinicals is pleased to announce the hire of Michael S. Willett, PharmD, RAC as the newest Senior Advisor for our clinical and scientific affairs team. Dr. Willett provides senior scientific input into the design and execution of early phase clinical trials. Dr. Willett has over 30 years of experience in clinical research and started his career at Marion Laboratories and Bristol-Myers Squibb where he was involved in…
AXIS Clinicals Announces New Clinical Operations in China.
Hyderabad, INDIA – AXIS Clinicals Limited (AXIS), a full-service clinical research organization (CRO), announces the opening of clinical operations in China with a Phase 1 BA/BE facility in Changsha, China in the province of Hunan. “Our New Phase 1 BA/BE Clinical Facility is established to support best in class research for innovative as well as generic pharmaceutical product development. This expansion compliments AXIS Clinicals continued growth in various geographies and…
AXIS Clinicals Announces New Clinical Operations in China.Read More
AXIS Clinicals USA Announces Enhanced Clinical Pharmacology Capabilities
Dilworth, MN – AXIS Clinicals is pleased to announce the expansion of our US clinical site with the addition of 45 hospital beds, offering the flexibility of 225 total beds in four clinical units and one outpatient unit. This addition compliments the original Dilworth facility design which was built to accommodate simultaneous studies of differing complexity. The addition of hospital beds highlights the current expansion of AXIS Clinicals in the…
AXIS Clinicals USA Announces Enhanced Clinical Pharmacology CapabilitiesRead More